TCP provides cytopathology review of cases submitted for the Afirma Genomic Sequencing Classifier. As members of the largest, thyroid-specialized cytopathology practice, TCP pathologists adhere to the established Bethesda criteria, which facilitate clear, definitive and confident cytopathology diagnoses.†
For nodules diagnosed as indeterminate*, the Afirma Genomic Sequencing Classifier (GSC)
is applied and can
objectively reclassify these cases as either benign1
or suspicious for malignancy. And, when you receive an Afirma GSC Suspicious result or a Bethesda V or VI cytopathology result, adding the Afirma Xpression Atlas
(XA) can provide additional genomic content to help inform surgery decisions and treatment options.